We are live on
!
Find out more
ProShare Advisors Portfolio holdings
AUM
$67.5B
1-Year Est. Return
28.09%
This Quarter
Est. Return
-4.85%
1 Year Est. Return
+28.09%
3 Year Est. Return
+88.43%
5 Year Est. Return
+118.21%
10 Year Est. Return
+464.8%
AUM
$46.6B
AUM Growth
-$4.41B
(-8.6%)
Cap. Flow
-$915M
Cap. Flow
% of AUM
-1.97%
Top 10 Holdings %
Top 10 Hldgs %
31.78%
Holding
2,365
New
27
Increased
297
Reduced
1,868
Closed
169
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Brown & Brown
BRO
|
+$161M |
| 2 |
Church & Dwight Co
CHD
|
+$150M |
| 3 |
Advanced Micro Devices
AMD
|
+$78.9M |
| 4 |
Old Dominion Freight Line
ODFL
|
+$56.9M |
| 5 |
AstraZeneca
AZN
|
+$53.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$170M |
| 2 |
AT&T
T
|
+$142M |
| 3 |
Microsoft
MSFT
|
+$136M |
| 4 |
XLNX
Xilinx Inc
XLNX
|
+$110M |
| 5 |
Amazon
AMZN
|
+$86.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.53% |
| 2 | Consumer Discretionary | 13.24% |
| 3 | Communication Services | 9.89% |
| 4 | Healthcare | 9.39% |
| 5 | Consumer Staples | 8.87% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2101
Lexicon Pharmaceuticals
LXRX
$1.02B
| $60K | ﹤0.01% |
28,535
-7,722
| -21% | -$21.4K |
|
|
LENZ
2102
LENZ Therapeutics
LENZ
$172M
| $60K | ﹤0.01% |
1,649
-27
| -2% | -$1.69K |
|
|
VBIV
2103
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $59K | ﹤0.01% |
1,178
-194
| -14% | -$9.59K |
|
2104
Veru
VERU
$36.1M
| $58K | ﹤0.01% |
1,208
-199
| -14% | -$10.8K |
|
2105
Accuray
ARAY
$28.4M
| $57K | ﹤0.01% |
17,246
-2,445
| -12% | -$9.1K |
|
2106
Quantum-Si Incorporated
QSI
$168M
| $57K | ﹤0.01% |
12,158
-4,385
| -27% | -$21.4K |
|
2107
Nautilus Biotechnolgy
NAUT
$215M
| $56K | ﹤0.01% |
12,877
-4,608
| -26% | -$18.9K |
|
2108
Safe Bulkers
SB
$781M
| $56K | ﹤0.01% |
11,880
-1,968
| -14% | -$8.03K |
|
|
URG
2109
Ur-Energy
URG
$485M
| $56K | ﹤0.01% |
34,763
-4,772
| -12% | -$6.75K |
|
2110
Kartoon Studios
TOON
$34.3M
| $54K | ﹤0.01% |
5,292
-874
| -14% | -$8.17K |
|
|
PSTX
2111
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $53K | ﹤0.01% |
11,861
-3,223
| -21% | -$14.5K |
|
2112
CytomX Therapeutics
CTMX
$705M
| $51K | ﹤0.01% |
18,904
-4,418
| -19% | -$17K |
|
2113
Invivyd
IVVD
$180M
| $51K | ﹤0.01% |
+11,037
| New | +$67.5K |
|
2114
Standard BioTools
LAB
$326M
| $51K | ﹤0.01% |
14,283
-2,363
| -14% | -$8.16K |
|
|
VIRX
2115
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
| $51K | ﹤0.01% |
10,656
-2,518
| -19% | -$7.59K |
|
|
EPZM
2116
DELISTED
Epizyme, Inc
EPZM
| $50K | ﹤0.01% |
43,486
+8,868
| +26% | +$14.5K |
|
2117
Precision BioSciences
DTIL
$188M
| $48K | ﹤0.01% |
525
-128
| -20% | -$17.4K |
|
2118
VistaGen Therapeutics
VTGN
$9.29M
| $46K | ﹤0.01% |
1,213
-200
| -14% | -$8.72K |
|
2119
TherapeuticsMD
TXMD
$23.8M
| $45K | ﹤0.01% |
2,342
-558
| -19% | -$8.78K |
|
2120
Spruce Power Holding Corp
SPRU
$39.9M
| $44K | ﹤0.01% |
+2,810
| New | +$48.9K |
|
|
MTEM
2121
DELISTED
Molecular Templates, Inc.
MTEM
| $44K | ﹤0.01% |
851
-216
| -20% | -$9.54K |
|
|
ZY
2122
DELISTED
Zymergen Inc. Common Stock
ZY
| $44K | ﹤0.01% |
15,032
-2,432
| -14% | -$10.3K |
|
2123
Ribbon Communications
RBBN
$354M
| $43K | ﹤0.01% |
13,884
-2,142
| -13% | -$8.78K |
|
|
PRTK
2124
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
| $43K | ﹤0.01% |
14,375
-3,383
| -19% | -$12.7K |
|
2125
Citius Pharmaceuticals
CTXR
$14.3M
| $42K | ﹤0.01% |
929
-63
| -6% | -$2.49K |
|
Similar funds
ProShare Advisors's Q1 2022 Portfolio in Review
As of Q1 2022, ProShare Advisors held 2,365 positions worth $46.6B, down 8.6% from $51B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
ProShare Advisors's Q1 2022 filing shows 27 new, 297 increased, 1,868 reduced and 169 closed positions. Its largest new stake was Constellation Energy: 594,655 shares worth $33.4M. The largest sale was Apple, an estimated $170M.
By sector, the portfolio is most concentrated in Technology at 32% of assets, down from 33% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- ProShare Advisors's largest Q1 2022 buy was Constellation Energy: 594,655 shares worth $33.4M.
- ProShare Advisors added most to Brown & Brown in Q1 2022, an estimated $161M increase.
- ProShare Advisors's biggest Q1 2022 reduction was Apple, cutting an estimated $170M.
- ProShare Advisors fully exited Xilinx Inc in Q1 2022, selling an estimated $110M.
- ProShare Advisors's ten largest holdings make up 32% of its $46.6B portfolio in Q1 2022.
- ProShare Advisors opened 27 new positions and closed 169 in Q1 2022.
- ProShare Advisors's portfolio value fell 8.6% quarter-over-quarter to $46.6B.
Based on ProShare Advisors's 13F filing for Q1 2022, filed 10 May 2022.